These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33560718)

  • 1. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
    Adnan A; Basu S
    Nucl Med Commun; 2021 May; 42(5):566-574. PubMed ID: 33560718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Added Value of
    Chen R; Wang Y; Zhu Y; Shi Y; Xu L; Huang G; Liu J
    J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival.
    Kurth J; Kretzschmar J; Aladwan H; Heuschkel M; Gummesson A; Bergner C; Kundt G; Hakenberg OW; Krause BJ; Schwarzenböck SM
    Nucl Med Commun; 2021 Nov; 42(11):1217-1226. PubMed ID: 34424870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters.
    Aksu A; Vural Topuz Ö; Yilmaz B; Karahan Şen NP; Acar E; Çapa Kaya G
    Nucl Med Commun; 2022 Apr; 43(4):468-474. PubMed ID: 35045552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Visually Calculated SUV
    Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
    J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137
    [No Abstract]   [Full Text] [Related]  

  • 9. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
    J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients.
    Oruç Z; Güzel Y; Ebinç S; Kömek H; Küçüköner M; Kaplan MA; Oruç İ; Urakçi Z; Işikdoğan A
    Nucl Med Commun; 2021 Dec; 42(12):1336-1346. PubMed ID: 34366407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Has Simsek D; Kuyumcu S; Karadogan S; Oflas M; Isik EG; Ozkan ZG; Paksoy N; Ekmekcioglu O; Ekenel M; Sanli Y
    Ann Nucl Med; 2021 Jun; 35(6):680-690. PubMed ID: 33783752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
    Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
    Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.
    Adnan A; Basu S
    PET Clin; 2022 Oct; 17(4):641-652. PubMed ID: 36153234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of tumor sink effect: Insights from
    Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
    Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of
    Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
    Santo G; Di Santo G; Zelger B; Virgolini I
    Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.